logo
More than 20 GOP attorneys general call on RFK Jr, FDA to reinstate safeguards for abortion drugs

More than 20 GOP attorneys general call on RFK Jr, FDA to reinstate safeguards for abortion drugs

Fox Newsa day ago
Print Close
By Landon Mion
Published August 13, 2025
EXCLUSIVE: More than 20 Republican attorneys general are demanding that the Trump administration reinstate safety protocols for the abortion drug mifepristone, saying it poses "serious risks to women."
In a letter obtained by Fox News Digital, 22 attorneys general called on Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drugs Administration head Martin Makary to bring back safeguards for the pills that were scrapped by the Obama and Biden administrations.
"Recent comprehensive studies of the real-world effects of the chemical abortion drug mifepristone report that serious adverse events occur 22 times more often than stated on the drug's label, while the drug is less than half as effective as claimed. These facts directly contradict the drug's primary marketing message of 'safe' and 'effective,'" the letter reads, citing studies published earlier this year by the Ethics and Public Policy Center (EPPA), a Washington, D.C.-based advocacy group.
The EPPA report claims the pill presents harm to women, causing 1 in 10 patients to experience a "serious adverse event," including hemorrhage, emergency room visits and ectopic pregnancy.
FDA CHIEF HAS 'NO PLANS' FOR ABORTION PILL POLICY CHANGES BUT CONTINUES SAFETY REVIEW
The letter, led by Kansas Attorney General Kris Kobach, comes after Kennedy Jr. asked Makary to review the latest data on mifepristone and its safety.
"Based on that review, the FDA should consider reinstating safety protocols that it identified as necessary as recently as 2011 in its issuance of a Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, but which were removed by the Obama and Biden administrations," the letter reads, adding that the drug should be taken off the market if safeguards cannot be put in place.
"Alternatively, in light of the serious risks to women who are presently being prescribed this drug without crucial safeguards, and in the event the FDA is unable to reinstate the 2011 safety protocols for mifepristone, the FDA should consider withdrawing mifepristone from the market until it completes its review and can decide on a course of action based on objective safety and efficacy criteria," the attorneys general wrote.
Sen. Josh Hawley, R-Mo., also sent a letter to Kennedy Jr. last month urging him to take immediate action to reinstate safety guardrails on mifepristone following the secretary's commitment to conducting a safety review of the drug.
Makary had previously said that he had no plans to modify policies surrounding mifepristone but that the FDA would act if the data suggested there was a safety issue.
Mifepristone, which is taken with another drug called misoprostol to end an early pregnancy, was first approved by the FDA in 2000 after "a thorough and comprehensive review" found it was safe and effective, according to the agency's website, which noted that periodic reviews since its approval have not identified new safety concerns.
Last year, the Supreme Court rejected a challenge targeting the drug's availability. The plaintiffs had sought to restrict access to mifepristone across the country, including in Democrat-led states where abortion remains legal. The court did not rule on whether the FDA acted lawfully when it moved during the Obama and Biden administrations to ease the rules for mifepristone's use that had been established during the Clinton administration.
Medication abortions made up more than half of all abortions in the U.S. health care system in 2023, according to a study by the Guttmacher Institute.
MEDICAL GROUPS URGE FDA, KENNEDY TO REEXAMINE BROAD APPROVAL OF ABORTION DRUGS
CLICK HERE TO GET THE FOX NEWS APP
"Currently, a woman can obtain a mifepristone abortion by participating in only one telehealth visit with any approved healthcare provider (not necessarily a physician), ordering the drugs through a mail-order pharmacy, and self-administering them," the attorneys general wrote. "And the prescriber is only required to report an adverse event if he or she becomes aware that the patient has died."
"The FDA's removal of these crucial safety protocols in 2016 (and in 2023) that only five years before the FDA considered necessary begs the question of whether the removal was motivated by considerations other than the safety of patients … The current FDA's dedication to the health and wellbeing of all Americans is encouraging, as is the much-needed review of mifepristone that Secretary Kennedy has promised," the letter concludes. Print Close
URL
https://www.foxnews.com/politics/more-than-20-gop-attorneys-general-call-rfk-jr-fda-reinstate-safeguards-abortion-drugs
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Democrats Plan Nationwide Protests Over Redistricting
Democrats Plan Nationwide Protests Over Redistricting

Epoch Times

timea few seconds ago

  • Epoch Times

Democrats Plan Nationwide Protests Over Redistricting

US Politics Organizers say rallies in more than 30 states aim to counter Trump-backed efforts to redraw congressional maps before 2026 elections. Democrats and allied advocacy groups are set to launch a series of protests on Saturday, Aug. 16, targeting Republican-led redistricting plans they say are designed to secure long-term control of the U.S. House. The 'Fight the Trump Takeover' National Day of Action, organized by the Democratic National Committee (DNC), the Texas for All coalition, and dozens of national and state partners, will feature nearly 150 rallies in at least 34 states.

Trump's debanking order could create headaches for banks, sources say
Trump's debanking order could create headaches for banks, sources say

Yahoo

time27 minutes ago

  • Yahoo

Trump's debanking order could create headaches for banks, sources say

By Nupur Anand, Pete Schroeder and Saeed Azhar NEW YORK (Reuters) -U.S. President Donald Trump's executive order requiring banks not to discriminate against clients on political or religious grounds could create uncertainty and administrative headaches for the industry, sources said. Trump signed an executive order on Thursday directing the Treasury Department and bank regulators to ensure lenders do not have policies in place that deny services to customers based on political or religious beliefs, a practice known as "debanking." Any wrongdoing uncovered could result in fines, disciplinary measures, and even referrals to the Justice Department. The order came days after Trump accused JPMorgan Chase and Bank of America last week of debanking him, and alleged that lenders discriminate against conservatives. Large banks have denied rejecting clients on political grounds, and instead blamed unclear rules for some of the account closures. Banks have earlier said that certain decisions to close accounts were based on rules around reputational risk, a criterion that has been banned by Trump's order. The order also gave regulators about 180 days to conduct their review. While some lenders welcomed the order for its potential to streamline processes, they also expressed concerns about how onerous it could be to comply with the order. The scope and zeal with which regulators carry out Trump's directions are still unclear and causing some trepidation, experts and industry officials said. "There are words in the executive order which can be open to interpretation," said Matt Bisanz, a partner at Mayer Brown. "We will have to see what meaning the regulators attach to it, and what is the scope of the activities that they focus on." "It's not even clear if there will be regulations or just guidance, which will be enforced through the bank exam process or will be handled in a quiet, non-public manner," Bisanz added. Trump's criticism echoed longstanding debanking complaints from Republicans, who have accused Wall Street banks of "woke capitalism," in denying services to gunmakers, fossil-fuel companies and others perceived to be aligned with the political right. "Fair access to financial services is a fundamental principle of the U.S. banking system," said Jonathan Gould, the Comptroller of the Currency, in a statement in response to the new order. "It is unacceptable for banks to discriminate against any customer on the basis of political or religious beliefs or lawful business activities." The OCC, which oversees national banks, is currently reviewing banks for improper policies and will take remedial actions "as appropriate." Spokespeople for the Federal Reserve and the Federal Deposit Insurance Corporation declined to comment on how they plan to implement the order. Industry executives say there are many questions about the executive order that may only be clarified if regulators publish rules on debanking, said three sources who declined to be identified because the discussions are private. It is too early to tell how onerous it will be to comply with the order given the lack of details so far, another industry source said. Banks could also face myriad challenges if they are forced to review and potentially renew client relationships over debanking, said Stephen Gannon, partner at Davis Wright Tremaine. Reinstating or modifying arrangements, as the order suggests, would require banks to analyze large volumes of data on client activities and products, he said. Regulators are unlikely to hand out penalties for any historic account closures, but they could be asked to disclose reasons for past debanking, two sources said. Now that the order has been announced, banks could face regulatory penalties if debanking guidelines are not properly implemented, said Ed Mills, an analyst at Raymond James, a financial services firm. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

POP Launches Canine Health Study with Innovative Pet Lab and Embark to Advance Data-Driven Pet Wellness
POP Launches Canine Health Study with Innovative Pet Lab and Embark to Advance Data-Driven Pet Wellness

Yahoo

time27 minutes ago

  • Yahoo

POP Launches Canine Health Study with Innovative Pet Lab and Embark to Advance Data-Driven Pet Wellness

New U.S.-based study will explore the impact of gut-focused nutrition, DNA insights, and activity tracking on canine immunity and long-term vitality HOUSTON, Aug. 14, 2025 /PRNewswire/ -- Pet wellness company POP today announced the launch of a 90-day canine health study in collaboration with Innovative Pet Lab, and Embark Veterinary. Designed to explore how personalized nutrition, biological data, and behavior tracking can support immune health and long-term vitality, the study will enroll up to 100 dogs from across the United States. Participants will receive over $600 in free health tools, including POP's science-backed supplement POP-Topper, Innovative Pet Lab's gut biomarker test kits, and Embark's DNA test. The study will also deliver a personalized health report at the end of the 90 days, combining insights from multiple data sources. "Dogs can't always tell us when something's off—but their biology and behavior can," said Alan Tsui, Co-Founder of POP. "We're combining cutting-edge diagnostics, personalized nutrition, and real-world data to give pet parents a clearer picture of their dog's health—and contribute to a future where all dogs live longer, healthier lives." POP, short for "Power of Pets," launched in 2024 to address the growing need for preventative pet health solutions rooted in science and personalization. Its flagship product, POP-Topper, is a functional food topper formulated with clinically studied ingredients that support gut health and reduce inflammation. Innovative Pet Lab will provide two at-home gut health test kits per participant to measure key markers like calprotectin, zonulin, and SIgA. Embark Veterinary, the global leader in dog DNA testing, will offer breed, trait, and genetic risk profiling to support individualized interpretation. This comprehensive study will investigate how a personalized protocol—combining diet, gut diagnostics, DNA, and behavior data—can inform smarter, more proactive dog care. Results will also contribute to future research on the early detection and prevention of chronic diseases like IBD, arthritis, and obesity. Enrollment is now open for dog owners in the U.S. with dogs aged 1–6 years. Participants must commit to feeding POP-Topper daily, submitting samples, and completing a series of surveys and weekly logs. Those who complete the study will receive a full refund of their $99 deposit. To learn more or apply, visit: About POPPOP (Power of Pets) is a next-generation pet health company dedicated to extending canine healthspan—the years dogs spend thriving, not just surviving. POP combines science-backed supplements and personalized diagnostics to help pet parents make better health decisions. Learn more at About Innovative Pet LabInnovative Pet Lab is a leader in canine gut health screening tests. Their at-home testing kits translate microbiome and immune biomarkers into actionable insights, empowering earlier intervention and improved long-term outcomes for dogs. About Embark VeterinaryEmbark offers the most comprehensive dog DNA test on the market. Developed by veterinarians and geneticists, Embark provides breed breakdowns, health risk screening, and trait insights to support proactive care. View original content to download multimedia: SOURCE POP LABS (Pet Longevity Research Limited) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store